Clinical trial NCT00275431: Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Official title: A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Follicular Lymphoma
Diffuse Large Cell Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Keywords: cancer
AT-101
AT101
B-cell malignancies
Non-Hodgkin
lymphoma
lukemia
Lead sponsor: Ascenta Therapeutics
Sponsor class: INDUSTRY
First posted: 2006-01-12
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.

Detailed description: This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies. For the purpose of this study, B-cell malignancies can include one of the following disease sub-types: follicular lymphoma (FL), diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia. Patients will be enrolled according to disease subtype into one of four groups in two stages. The first stage of each group will enrolled 13 patients. If patients within any group experience disease response, an additional 14 patients will be enrolled into that group.

Eligibility criteria: Inclusion Criteria:

* Must have a histologically confirmed B-cell malignancy (defined as FL \[any grade\], DLBCL, MCL or SLL/CLL);
* Male or non-pregnant, non-lactating females age ≥18 years;
* Ability to swallow and retain oral medication.;
* Have failed at least one prior therapy and have documentation of either, relapsed disease, or refractory disease (i.e., no response or stable disease on their last regimen of therapy);
* ECOG performance status 0 or 1;
* All clinically significant toxicities from prior therapy must have fully resolved;
* Must have discontinued treatment with monoclonal antibodies for a minimum of 90 days prior to first dose of AT-101, or have objective documentation of disease progression if within 90 days of monoclonal antibody administration;
* Patients with FL, DLBCL, MCL, and SLL with normal lymphocyte counts must have at least one bi-dimensional lesion that is radiographically measurable (skin lesions, palpable lymph nodes, and bone marrow as the only site of disease are not considered measurable disease);
* Patients with SLL whose lymphocytes are elevated at baseline or CLL must have palpable lymph nodes and/or disease localized to the bone marrow per the NCI-Sponsored Working Group Guidelines for CLL.

Exclusion Criteria:

* Requirement of systemic corticosteroids within 7 days prior to and during AT-101 administration;
* Must not have received anti-cancer therapy within 28 days of first dose of AT-101. Cannot have received hormonal agents or biologic dose modifiers (with the exception of HRT) or any investigational treatments within 28 days of treatment with AT-101;
* Patients with CNS lymphoma, HIV-related lymphoma, symptoms suggesting HIV infection or active auto-immune hemolytic anemia are excluded;
* Previous treatment with gossypol, or are hypersensitive to its excipient are excluded;
* Patients who have an uncontrolled, concurrent illness are also excluded.

Primary outcomes:
measure: Complete or partial remission of disease.
timeFrame: every 6 weeks
Secondary outcomes:
measure: Number of participants with adverse events.
timeFrame: every 3 weeks
measure: duration of response
timeFrame: every 6 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: San Diego
country: United States
state: California
city: Atlanta
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Boston
country: United States
state: Massachusetts
city: New York
country: United States
state: New York
city: Rochester
country: United States
state: New York
city: High Point
country: United States
state: North Carolina
city: Hilton Head Island
country: United States
state: South Carolina
city: Memphis
country: United States
state: Tennessee
city: Burlington
country: United States
state: Vermont
Study officials:
affiliation: Ascenta Therapeutics, Inc.
name: Lance Leopold, MD
role: STUDY_DIRECTOR
References: